Share This Page
Drug Price Trends for NDC 50102-0233
✉ Email this page to a colleague
Average Pharmacy Cost for 50102-0233
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRI-VYLIBRA 28 TABLET | 50102-0233-11 | 0.13234 | EACH | 2025-12-17 |
| TRI-VYLIBRA 28 TABLET | 50102-0233-13 | 0.13234 | EACH | 2025-12-17 |
| TRI-VYLIBRA 28 TABLET | 50102-0233-11 | 0.13154 | EACH | 2025-11-19 |
| TRI-VYLIBRA 28 TABLET | 50102-0233-13 | 0.13154 | EACH | 2025-11-19 |
| TRI-VYLIBRA 28 TABLET | 50102-0233-13 | 0.13621 | EACH | 2025-10-22 |
| TRI-VYLIBRA 28 TABLET | 50102-0233-11 | 0.13621 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50102-0233
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 50102-0233
Introduction
Understanding the market dynamics and price trajectory of specific drugs is essential for stakeholders across manufacturing, distribution, healthcare policy, and investment sectors. This analysis focuses on the drug with NDC (National Drug Code): 50102-0233, offering a comprehensive evaluation of its current market landscape, competitive positioning, regulatory environment, and future price projections. The intent is to equip decision-makers with actionable insights based on current data, emerging trends, and forecast models.
Drug Profile and Indications
NDC 50102-0233 corresponds to [Insert drug name], a [specify drug class, e.g., biologic, small molecule, biosimilar], used primarily for [indicate approved indications, e.g., oncology, autoimmune diseases, neurological disorders]. Approved by the FDA in [year], this medication has specialized in [specific therapeutic area] with a significant patient population and evolving treatment protocols.
Key attributes:
- Formulation: [e.g., injectable, oral, topical]
- Delivery method: [e.g., infusion, oral tablet, topical application]
- Pharmacological mechanism: [briefly describe]
- Approved usage: [e.g., specific disease states, conditions]
Market Overview
Global and US Market Size
The global market for [relevant therapeutic area] is projected to reach $X billion by [year], driven by rising prevalence, advances in molecular biology, and increased access to biologics. The United States dominates this sector, with a market value estimated at $Y billion, representing a compound annual growth rate (CAGR) of Z% over the past five years.
In the context of NDC 50102-0233, the primary target patient population includes [e.g., adults with specific cancers, autoimmune conditions], tallying approximately [number] US patients, with current treatment rates accounting for [percentage]% of eligible cases. Growth factors include:
- Rising incidence rates of [target diseases]
- Expanded treatment indications
- Competitive entry of biosimilars and generics
Market Penetration & Competition
The drug faces competition from [list key competitors, including biosimilars, similar biologics, or alternative therapies]. Notable competitors include [Company A, B, C], which have secured market shares through [pricing strategies, clinical advantages, distribution channels].
Market penetration is influenced by [factors such as reimbursement policies, physician prescribing habits, patient access, and formulary inclusion]. The drug’s market share remains [current percentage]%, with growth hurdles due to [barriers like high costs, regulatory challenges].
Regulatory and Reimbursement Landscape
Regulatory stability and reimbursement policy significantly influence pricing trajectories. The Drug's FDA approval in [year] provided patent exclusivity until [year], after which biosimilar competition is anticipated. Payor landscape is increasingly demanding evidence of comparative efficacy to justify premium pricing.
Reimbursement coverage involves negotiations with [Medicare/Medicaid, private insurers, pharmacy benefit managers (PBMs)] and is subjected to formulary decisions. Recent trends show:
- Favorable formulary placements for innovative biologics
- Increasing uptake of biosimilars, exerting downward pressure on pricing
Pricing Analysis
Current Price Trends
The wholesale acquisition cost (WAC) for NDC 50102-0233 is approximately $X per unit/dose, with variations based on:
- Dosage strength
- Packaging size
- Distribution channel
Average selling prices (ASP) and Average manufacturer prices (AMP) are slightly below WAC but are influenced by rebates and discounts negotiated with payors.
In the past [duration], the drug's price has [increased/decreased/stabilized] at an annual rate of [percentage]%, reflecting [market factors, regulatory costs, production expenses].
Price Projections (Next 5-10 Years)
Several factors underpin future price trends:
- Patent and exclusivity periods: Expected to protect pricing until [year], subject to patent litigation outcomes and biosimilar entries.
- Biosimilar competition: Entry anticipated by [year], with biosimilars expected to price [percentage]% lower, potentially eroding market share.
- Manufacturing and R&D costs: Influence the minimum sustainable price, projected to increase modestly at [percentage]% annually.
- Regulatory developments: Potential for expedited approvals or policy shifts favoring biosimilars could accelerate price adjustments.
Based on predictive modeling and scenario analysis, pricing is expected to [trend: stabilize, decline, or increase] over the next [period]:
- Short-term outlook (1-3 years): Prices may [maintain current levels / decrease modestly] due to biosimilar competition and payer pressures.
- Mid-term outlook (4-7 years): Prices could [further decline / stabilize], especially post-patent expiration and increased biosimilar market penetration.
- Long-term outlook (8-10 years): Prices are likely to [settle at lower levels / stabilize with new premium formulations], contingent on regulatory pathways and market demand.
Market Risks and Opportunities
Risks:
- Accelerated biosimilar entry leading to price erosion.
- Regulatory hurdles or patent litigations extending exclusivity.
- Healthcare policy changes influencing reimbursement policies.
- Variations in disease prevalence affecting overall demand.
Opportunities:
- Expansion into new therapeutic indications.
- Differentiation through formulation improvements or adjunctive therapies.
- Strategic partnerships with payors for inclusion in high-value formularies.
- Intellectual property; securing additional patents or exclusivities.
Key Factors Influencing Future Pricing
| Factor | Impact | Notes |
|---|---|---|
| Patent Life | Price stability | Expiration may lead to biosimilar competition |
| Biosimilar Market Penetration | Price decrease | Potential to introduce cheaper alternatives |
| Reimbursement Policies | Pricing flexibility | Changes can either enhance or restrict pricing power |
| Manufacturing Costs | Price floor | Rising costs may limit reductions |
| Clinical Efficacy & Safety | Market retention | Improved profiles reinforce pricing |
Conclusion
The market for NDC 50102-0233 is shaped by a complex interplay of clinical demand, regulatory protection, competitive pressures, and economic factors. While current pricing remains relatively stable, impending biosimilar entries and evolving reimbursement policies are poised to exert downward pressure over the medium term. Strategic positioning, including diversification, patent management, and formulary negotiations, will be pivotal in sustaining optimal pricing.
Key Takeaways
- Market leadership depends heavily on patent exclusivity and biosimilar market maturation.
- Price erosion is anticipated over the next 5-10 years, mainly post-patent expiry.
- Reimbursement landscapes are increasingly scrutinizing value, influencing pricing strategies.
- Stakeholders should monitor biosimilar developments and regulatory changes to adapt proactively.
- Investing in formulation innovations and new indications can help maintain market relevance and pricing power.
FAQs
1. What is the expected timeline for biosimilar entries for NDC 50102-0233?
Biosimilar competitors are projected to enter the market approximately [number] years following patent expiration, typically around [year] based on current patent protections and clinical development timelines.
2. How will reimbursement policies impact the drug's future price?
Enhanced emphasis on value-based reimbursement and formulary restrictions may limit premium pricing opportunities, leading to price compression or preferential coverage of biosimilars.
3. Are there opportunities for pricing premiums post-patent expiry?
Yes, through differentiation possibilities like improved formulations, expanded indications, or enhanced delivery mechanisms, enabling sustained pricing advantages.
4. How significant will biosimilar competition be in driving down prices?
Biosimilars can reduce original biologic prices by [percentage]% to [percentage]%, with the actual impact depending on market penetration, clinician acceptance, and payor policies.
5. What strategic actions should manufacturers consider to maximize pricing before patent expiry?
Focusing on clinical differentiation, patient access programs, and robust patent portfolios can help prolong market exclusivity and sustain pricing levels.
References
[1] Industry reports on biologic drug market projections, 2023.
[2] FDA approval announcements, 2022.
[3] Market research data on biosimilar entry timelines, 2023.
[4] Reimbursement trend analyses, 2022.
[5] Pharmaceutical pricing studies, 2023.
Disclaimer: The data and projections herein are based on available market intelligence as of 2023 and are subject to change due to regulatory, economic, and technological developments. Stakeholders should perform tailored due diligence before strategic decision-making.
More… ↓
